KEYNOTE-689: A Phase 3 Study of Neoadjuvant and Adjuvant Pembrolizumab Plus Standard of Care (SOC) in Resectable, Locally Advanced (LA) Head and Neck Squamous Cell Carcinoma (HNSCC)

Клочихин, А. Л.; Haddad, Robert I.; Meirovitz, Amichay; Safina, Sufia; Braña, Irene; Tourneau, Christophe Le; Uppaluri, Ravindra; Lee, Nancy Y.; Cohen, Ezra E.W.; Chernock, Rebecca D.; Westra, William H.; Liu, Hong; Gümüşçü, Burak; Benjamin, Kimberly; Adkins, Douglas

doi:10.1016/j.ejso.2022.11.056

European Journal of Surgical Oncology

2023

DOI: 10.1016/j.ejso.2022.11.056

|View full text |Cite

KEYNOTE-689: A Phase 3 Study of Neoadjuvant and Adjuvant Pembrolizumab Plus Standard of Care (SOC) in Resectable, Locally Advanced (LA) Head and Neck Squamous Cell Carcinoma (HNSCC)

А. Л. Клочихин¹,

Robert I. Haddad

Amichay Meirovitz

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A small randomized Phase II study has already demonstrated positive effects of neoadjuvant pembrolizumab in terms of tolerance and response (18). Currently, a randomized Phase III trial (KEYNOTE-689) is evaluating the efficacy and safety of pembrolizumab as neoadjuvant and adjuvant therapy (19). Targeted therapy aims to reduce tumor volume, slow tumor progression, and ultimately prolong OS.…”

mentioning

confidence: 99%

Evaluation of Five-year Overall Survival Rates Among 18,331 Head and Neck Cancer Patients Exposed to Different Targeted Therapies Through Real-world Data in a Case-controlled Study

BAUDREXL,

SAKKAS,

PIETZKA

et al. 2024

Anticancer Res

View full text Add to dashboard Cite

Background/Aim: Targeted therapy is an important and fast developing aspect of modern tumor therapy including therapy of head and neck cancer (HNC). Surgically treated patients often experience significant limitations to their ability to swallow, speak, or mimic expressions. In cases of recurrent tumors or palliative situations, targeted therapies such as immune checkpoint inhibitors (ICI) are frequently employed. This study compared different targeted therapies focusing on survival probability. Patients and Methods: Data from patients with head and neck cancer treated with different therapy regimens from the TriNetX network were analyzed. Two groups were formed: Cohort I received one targeted therapy, whereas patients in cohort II received a different targeted therapy. Cohorts I and II were matched 1:1 with respect to certain confounders. After defining the primary outcome as "death", a Kaplan-Meier analysis was performed, and the risk ratio (RR), odds ratio (OR), and hazard ratio (HR) were calculated. Results: A total of 18,331 patients with HNC treated with targeted therapy were analyzed. Patients treated with VEGF inhibitors had a significantly longer overall survival than patients treated with c-MET or EGFR inhibitors. Patients treated with PI3K inhibitors showed a significantly reduced survival probability compared to those treated with c-MET, mTOR, and RET inhibitors. Conclusion: EGFR inhibitors are one of the most frequently used targeted therapies in HNC. However, in the present analysis, a survival advantage of patients treated with c-MET inhibitors or VEGF inhibitors was observed compared to those treated with EGFR inhibitors.Head and neck cancer (HNC) is one of the most common malignancies in the world. The most frequent histological tumor entity of HNCs is the Head and Neck Squamous Cell Carcinoma (HNSCC) (1). Treatment typically involves extensive surgical procedures, including the use of free or pedicled flaps, and adjuvant combined radiochemotherapy if required, in accordance with national guidelines. However, the 5-year overall survival rate for patients with this type of cancer is currently only 50% (2, 3). Surgically treated patients often experience significant limitations to their ability to swallow, speak, or mimic expressions (4). In cases of recurrent tumors or palliative situations, targeted therapies such as immune checkpoint inhibitors (ICIs) are frequently employed. International guidelines recommend the use of targeted therapy as a first-or second-line palliative treatment (5-8). Therefore, it may be useful to compare different targeted therapies in terms of overall survival (OS) in order to offer the palliative patient the therapy with the longest OS when choosing between two targeted therapies.The first-line targeted therapy for recurrent or metastatic HNSCC is the use of programmed cell death ligand-1 (PD-L1) inhibitors, also known as ICIs such as pembrolizumab or nivolumab (9). PD-1 is expressed on both immune and cancer cells, suppressing T cell activity and preventing the immune...

show abstract

mentioning

confidence: 99%

Evaluation of Five-year Overall Survival Rates Among 18,331 Head and Neck Cancer Patients Exposed to Different Targeted Therapies Through Real-world Data in a Case-controlled Study

BAUDREXL,

SAKKAS,

PIETZKA

et al. 2024

Anticancer Res

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

KEYNOTE-689: A Phase 3 Study of Neoadjuvant and Adjuvant Pembrolizumab Plus Standard of Care (SOC) in Resectable, Locally Advanced (LA) Head and Neck Squamous Cell Carcinoma (HNSCC)

Cited by 1 publication

References 0 publications

Evaluation of Five-year Overall Survival Rates Among 18,331 Head and Neck Cancer Patients Exposed to Different Targeted Therapies Through Real-world Data in a Case-controlled Study

Evaluation of Five-year Overall Survival Rates Among 18,331 Head and Neck Cancer Patients Exposed to Different Targeted Therapies Through Real-world Data in a Case-controlled Study

Contact Info

Product

Resources

About